Surgery – Radioactive substance applied to body for therapy
Reexamination Certificate
2009-03-31
2011-10-11
Marmor, II, Charles A (Department: 3735)
Surgery
Radioactive substance applied to body for therapy
Reexamination Certificate
active
08033977
ABSTRACT:
The present invention provides methods of using metal nanoparticles 0.5 to 400 nm in diameter to enhance the dose and effectiveness of x-rays or of other kinds of radiation in therapeutic regimes of ablating a target tissue, such as tumor. The metal nanoparticles can be administered intravenously, intra-arterially, or locally to achieve specific loading in and around the target tissue. The metal nanoparticles can also be linked to chemical and/or biochemical moieties which bind specifically to the target tissue. The enhanced radiation methods can also be applied to ablate unwanted tissues or cells ex vivo.
REFERENCES:
patent: 4269826 (1981-05-01), Zimmermann et al.
patent: 4515954 (1985-05-01), Lang, Jr. et al.
patent: 4652449 (1987-03-01), Ropars et al.
patent: 4657763 (1987-04-01), Finkelstein
patent: 4839111 (1989-06-01), Huang
patent: 4935223 (1990-06-01), Phillips
patent: 5163896 (1992-11-01), Suthanthiran et al.
patent: 5292524 (1994-03-01), Male et al.
patent: 5360895 (1994-11-01), Hainfeld et al.
patent: 5521289 (1996-05-01), Hainfeld et al.
patent: 5542936 (1996-08-01), Razi
patent: 5612207 (1997-03-01), Nicolau et al.
patent: 5688486 (1997-11-01), Watson et al.
patent: 5690903 (1997-11-01), Hainfeld
patent: 5948384 (1999-09-01), Filler
patent: 6001054 (1999-12-01), Regulla et al.
patent: 6125295 (2000-09-01), Cash, Jr. et al.
patent: 6165440 (2000-12-01), Esenaliev
patent: 6369206 (2002-04-01), Leone et al.
patent: 6506145 (2003-01-01), Bradshaw et al.
patent: 6530944 (2003-03-01), West et al.
patent: 6645464 (2003-11-01), Hainfeld
patent: 6955639 (2005-10-01), Hainfeld et al.
patent: 7367934 (2008-05-01), Hainfeld et al.
patent: 7530940 (2009-05-01), Hainfeld et al.
patent: 2003/0185757 (2003-10-01), Kresse et al.
patent: 2005/0180917 (2005-08-01), Patel
patent: WO 0006244 (2000-02-01), None
patent: WO 2004112590 (2004-12-01), None
patent: WO 2004112590 (2004-12-01), None
Castillo Manuel H, et. al., “Effects of Radiotherapy on Mandibular Reconstruction Plates”,The American Journal of Surgery156: 261-263 (1988).
Regulla D.F. et. al., “Physical and Biological Interface Dose Effects in Tissue due to X-Ray Induced Release of Secondary Radiation from Metallic Gold Surfaces”,Radiation Research150: 92-100 (1998).
Das Indra J. et. al., “Backscatter dose perturbation in kilovoltage photon beams at high atomic number interfaces”,Medical Physics22(6): 767-773 (1995).
Herold D.M. et. al. “Gold microspheres: a selective technique for producing biologically effective dose enhancement”,International Journal of Radiation Biology76(10): 357-1364 (2000).
Matsudaira H. et. al., “Iodine Contrast Medium Sensitizes Cultured Mammalian Cells to X Rays but not to γ Rays”,Radiation Research84: 144-148 (1980).
Prime K. L. et al., “Self-Assembled Organic Monolayers: Model Systems for Studying Adsorption of Proteins at Surfaces”,Science252: 1164-1167 (1991).
Allen T. M. et al., “Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo”,Biochimica et Biophysica Acta1066: 29-36 (1991).
Woodle M. C. et al., “Sterically stabilized liposomes”,Biochimica et Biophysica Acta1113: 171-199 (1992).
Papahadjopoulos D. et al., “Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy”,Proc. Natl. Acad. Sci. USA 88: 11460-11464 (1991).
Mian, T.A. et al., “Backscatter radiation at bone-titanium interface from high-energy X and gamma rays”, Int. J. Radiation Oncol. Biol. Phys., 13, pp. 1943-1947, (1987).
Huq, M.S. et al., “The effect on dose of kilovoltage x-rays backscattered from lead”, Int. J. Radiation Oncol. Biol. Phys.,24,pp. 171-175,(1992).
Verhaegen, F., and Seuntjens, J., “Monte Carlo study of electron spectra and dose from backscattered radiation in the vicinity of media interfaces for monenergtic photons of 50-1250 keV”, Radiation Res., 143, pp. 334-342, (1995).
Gagnon, W.F., and Cundiff, J.H., “Dose enhancement from backscattered radiation at tissue-metal interfaces irradiated with high energy electrons”, British J. Radiology, 53, pp. 466-470, (1980).
Johnson, D.H., “Phase III trial (E5592) comparing cisplatin plus etoposide with cisplatin plus paclitaxel at two dose levels for treatment of advanced non-small-cell lung cancer”, Eastern Cooperative Oncology Group. J. Natl. Cancer Inst. Monogr.;(19):61-3. (1995).
Baselga, J., et al. “Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2
eu-overexpressing metastatic breast cancer”, J. Clin. Oncol. 14(3):737-44, Mar. 1996.
Hung, M.C, et al. “HER-2
eu-targeting gene therapy-a review”, Gene, 159(1):65-71, Jun. 1995.
Yan, D.H. “Targeting human breast cancer cells that overexpress HER-2
eu mRNA by an antisense iron responsive element”, Biochem. Biophys. Res. Commun.; 246(2):353-8 May 1998.
Fidler, I.J., et al., “Molecular determinants of angiogenesis in cancer metastasis”, Cancer J. Sci. Am., 4 Suppl 1: S58-66, May 1998.
Presta, L.G., et al., “Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders”, Cancer Res. 57(20):4593-9, Oct. 1997.
Boehm, T., et al., “Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance”, Nature, 390(6658):404-7, Nov. 1997.
Dass, C.R., et al., “Enhanced anticancer therapy mediated by specialized liposomes”, J. Pharm. Pharmacol.,49 (10):972-5, Oct. 1997.
Gahbauer, R., et al. “Boron neutron capture therapy: principles and potential”, Recent Results Cancer Res.,150:183-209, abstract only, (1998).
Faivre-Chauvet, A., et al., “Pre-clinical and clinical studies of two new bifuntional chelating agents for immunoscintigraphy with 111 In-anti-CEA monoclonal antibody”, Nucl. Med. Commun., 17(9):781-9, Sep. 1996.
McNamara, D.A., et al., “Significance of angiogenesis in cancer therapy”, Br. J. Surg., 85(8):1044-55, Aug. 1998.
Huang, X., et al., “Tumor infarction in mice by antibody-directed targeting factor to tumor vasculature”, Science, 275 (5299):547-50, (1997).
Calabrese, L.C., and Wholey, M.H., “Arterial imaging”, Curr. Opin. Cardiol., 7(5):843-50, Oct. 1992.
Handley, D. A. in Hayat, M. A. (Ed.), “Colloidal Gold: Principles, Methods, and Applications”, Academic Press, vol. 1, pp. 1-32, San Diego, CA. (1989).
De Harven, E., et al., “Antibody drug carrier for immunotherapy of superficial bladder cancer: ultrastructural studies”, Cancer Res. 52(11):3131-7, Jun. 1, 1992.
Material Safety Data Sheet, “Gold”, Johnson Matthey Aesar Group, 1985.
Hillyer, J.F. and Albrecht, R.M, “Micros. and Microanal.”, Bailey, GW, ed. p. 998 (1998).
Brown, J.M., and Giacca, A.J. “The unique physiology of solid tumors: opportunities (and problems) for cancer therapy”, Cancer Res., 58(7):1408-16, Apr. 1998.
Mittleman, A. “Life-threatening toxicity of cancer therapy”, Crit. Care Clin. 4, 1-9, (1988).
Moore, I.M., “Central nervous system toxicity of cancer therapy in children”, J. Pediatr. Oncol. Nurs., 12(4):203-10; discussion 211, Oct. 1995.
Maher, L.J. 3rd, “Prospects for the therapeutic use of antigene oligonucleotides”, Cancer Invest., 14(1):66-82, (1996).
Qasim, F.J., et al., “Gold and D-penicillamine induce vasculitis and up-regulate mRNA for IL-4 in the Brown Norway rat: support for a role for Th2 cell activity”, Clin. Exp. Immunol.,108(3):438-45, Jun. 1997.
Takahashi Y., et al. “The utility of chelating agents as antidotes for nephrotoxicity of gold sodium thiomalate in adjuvnat-arthritic rats”, Toxicology, 97(1-3):151-7, Mar. 1995.
Tomioka, R., and King, T.E., Jr., “Gold-induc
Hainfeld James F.
Slatkin Daniel N.
Hopkins Christine
Marmor II Charles A
NanoProbes, Inc.
Scully , Scott, Murphy & Presser, P.C.
LandOfFree
Methods of enhancing radiation effects with metal nanoparticles does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of enhancing radiation effects with metal nanoparticles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of enhancing radiation effects with metal nanoparticles will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4299873